Jimmy Schmidt is a Dermatology physician affiliated with DermSurgery Associates. OpenAlex indexes 5 publications with 246 citations (h-index 4).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
819 Peakwood Dr
Houston, TX 770902905
Telephone
281-444-1288Provider last certified this registry record 14 Aug 2023.
Industry payments
22 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Janssen Biotech, Inc.Program year202412 payments
- ABBVIE INC.Program year202411 payments
- SUN PHARMACEUTICAL INDUSTRIES INC.Program year20246 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
38.3%Tetracycline-class Drug17%Doxycycline Hyclate53%Doxycycline Monohydrate27%Minocycline Hcl20%Part D<11 patientsAzole Antifungal13.5%Ketoconazole100%Part D≥95 patients+ 3 more classes in this area
Dermatology
29.5%Corticosteroid19.3%Triamcinolone Acetonide100%Part D≥159 patientsInterleukin-4 Receptor alpha Antagonist8%Dupixent Pen60%Dupixent Syringe40%Part D<11 patients+ 1 more class in this area
Sensory organs
13.1%Corticosteroid13.1%Hydrocortisone53%Betamethasone Dipropionate28%Clobetasol Propionate19%Part D≥56 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Treatment of Bullous Pemphigoid With Dupilumab: A Case Series of 30 Patients
Journal of Drugs in Dermatology
2024 - Die Rolle von endothelialen ICAM-1 und β2-Integrinen in der Leukozytenrekrutierung beim experimentellen HCC
Zeitschrift für Gastroenterologie
2010 - Fluoroscopy-induced chronic radiation dermatitis: A report of three cases
Dermatology Online Journal
2009
Similar KOLs
Other experts from the same institution or the same specialty.
Robert Modlin, MD
University of California, Los Angeles
Heidi Kong, MD
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Jon Hanifin, MD
Oregon Health & Science University (OHSU)
Victoria Werth, MD
Perelman School of Medicine at the University of Pennsylvania
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”